ACE2-based Peptide for SARS-CoV-2 Treatment
The novel coronavirus (SARS-CoV-2) occurred in Wuhan, Hubei Province, China in December of 2019. SARS-CoV-2 has resulted in thousands of people of lethal disease in China and more and more patients have been diagnosed in the world. This novel coronavirus was reported to share the same receptor, angiotensin-converting enzyme 2 (ACE2), with SARS-Cov. Creative Biolabs is executing our strategy to bring comprehensive ACE2-based peptide services to our clients for SARS-CoV-2 researches. Creative Biolabs can help pharma and biopharma to decrease the attrition rate of peptide candidates in the peptide drug discovery projects by our sophisticated technologies, scientists and technicians.
ACE2 is one of the M2 metalloprotease family members but functions as carboxypeptidase (as opposed to ACE which is a peptidyl dipeptidase) via removing the C-terminal residue from its peptide substrates. Although the binding strength between SARS-CoV-2 and ACE2 is weaker than that between SARS-Cov and ACE2, it is still much higher than the threshold required for virus infection. The further analysis demonstrates that the region covering amino acids 318-520 of spike (S) protein is the key receptor-binding domain (RBD), which is both essential and sufficient to bind the human ACE2 molecule in vitro. As for the S protein of coronavirus, it is responsible for attachment to cellular receptor to start the first step of virus infection. Model of the structure of ACE2 is shown in Fig.1, showing the active site residues and an enlarged schematic of residues (in black) coordinating the zinc ion including the proposed reaction intermediate.
Fig.1 ACE2 model and a close-up schematic view of the active site. (Guy, 2003)
ACE2 is a membrane-bound ecto-enzyme that can be found in soluble form within the plasma and tissues such as heart, liver, kidney, brain and blood vessels. Therefore, ACE2 is an important drug target for the researches and treatment of hypertension, heart, kidney, and lung disease. Recently, many studies indicated that ACE2 has also been identified to be a functional receptor of the SARS coronavirus. In other words, ACE2 may be a promising target for the researches or/treatments of SARS-CoV-2.
With our advanced technologies and experienced staffs, Creative Biolabs provides ACE2-based peptide research services for customers all over the world. We also offer personalized experimental design and excellent support based on customers’ special requirements. If you are interested in ACE2-based peptide, please feel free to contact us.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.